Mark Rutstein

1.7k total citations
26 papers, 1.3k citations indexed

About

Mark Rutstein is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Mark Rutstein has authored 26 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Mark Rutstein's work include Colorectal Cancer Treatments and Studies (6 papers), Platelet Disorders and Treatments (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Mark Rutstein is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Platelet Disorders and Treatments (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Mark Rutstein collaborates with scholars based in United States, Germany and Spain. Mark Rutstein's co-authors include Martin H. Teicher, Susan L. Andersen, Jon P. Fryzek, Fionna Mowat, Lin Li, W. Marieke Schoonen, Gena Kucera, Jenna E. Coalson, James A. Kaye and Robert P. Hasserjian and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American Society of Nephrology.

In The Last Decade

Mark Rutstein

26 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Rutstein United States 9 442 402 213 192 188 26 1.3k
Jessica A. Boyette-Davis United States 15 160 0.4× 189 0.5× 42 0.2× 163 0.8× 49 0.3× 22 1.3k
Pamela S. Hunt United States 25 720 1.6× 464 1.2× 242 1.1× 500 2.6× 224 1.2× 57 2.2k
Thaddeus J. Unger United States 15 417 0.9× 178 0.4× 39 0.2× 775 4.0× 42 0.2× 17 1.4k
M. Schroeder Israel 21 84 0.2× 120 0.3× 168 0.8× 345 1.8× 166 0.9× 74 1.2k
Nelson B. Freimer United States 9 140 0.3× 93 0.2× 46 0.2× 109 0.6× 40 0.2× 15 705
Christopher W. Smith United Kingdom 19 214 0.5× 56 0.1× 46 0.2× 253 1.3× 48 0.3× 36 1.4k
John Logothetis United States 19 124 0.3× 242 0.6× 45 0.2× 173 0.9× 27 0.1× 56 1.4k
Bei Shao China 23 24 0.1× 149 0.4× 86 0.4× 333 1.7× 124 0.7× 65 1.5k
Jiayu Fu China 14 50 0.1× 206 0.5× 49 0.2× 187 1.0× 54 0.3× 62 768

Countries citing papers authored by Mark Rutstein

Since Specialization
Citations

This map shows the geographic impact of Mark Rutstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rutstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rutstein more than expected).

Fields of papers citing papers by Mark Rutstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Rutstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rutstein. The network helps show where Mark Rutstein may publish in the future.

Co-authorship network of co-authors of Mark Rutstein

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Rutstein. A scholar is included among the top collaborators of Mark Rutstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Rutstein. Mark Rutstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burns, Leah, et al.. (2022). Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies. Advances in Therapy. 39(10). 4772–4778. 2 indexed citations
2.
3.
4.
5.
Lambrechts, Diether, R J Vonk, Mark Rutstein, et al.. (2016). PD-003 Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC). Annals of Oncology. 27. ii102–ii102. 3 indexed citations
6.
7.
Teufel, Michael, Susanne Schwenke, Henrik Seidel, et al.. (2015). Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.. Journal of Clinical Oncology. 33(15_suppl). 3558–3558. 20 indexed citations
8.
9.
Petrylak, Daniel P., Kim N., Nicholas J. Vogelzang, et al.. (2012). Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy.. Journal of Clinical Oncology. 30(15_suppl). TPS4675–TPS4675. 3 indexed citations
10.
11.
Martell, Robert E., E. Gabriela Chiorean, Hagop Youssoufian, et al.. (2011). Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.. Journal of Clinical Oncology. 29(15_suppl). TPS150–TPS150. 3 indexed citations
12.
13.
Surguladze, David, Mary Jane Plym, Marie Prewett, et al.. (2010). 231 Efficacy of VEGFR2 targeted mAb therapy in preclinical cancer models resistant to antiangiogenic therapy. European Journal of Cancer Supplements. 8(7). 75–75. 1 indexed citations
14.
Schoonen, W. Marieke, Gena Kucera, Jenna E. Coalson, et al.. (2009). Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. British Journal of Haematology. 145(2). 235–244. 215 indexed citations
15.
16.
Mathias, Susan D., Sue Gao, Mark Rutstein, et al.. (2008). Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Current Medical Research and Opinion. 25(2). 375–383. 22 indexed citations
17.
Liebman, Howard A., David Henry, François Lefrère, et al.. (2008). Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).. Blood. 112(11). 3415–3415. 8 indexed citations
18.
Winkelmayer­, Wolfgang C., et al.. (2004). Pharmacoepidemiology of Anemia in Kidney Transplant Recipients. Journal of the American Society of Nephrology. 15(5). 1347–1352. 111 indexed citations
19.
Andersen, Susan L., et al.. (2000). Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats. Synapse. 37(2). 167–169. 351 indexed citations
20.
Andersen, Susan L., et al.. (1997). Sex differences in dopamine receptor overproduction and elimination. Neuroreport. 8(6). 1495–1497. 272 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica A. Boyette-Davis Breakdown of academic impact, for papers by Pamela S. Hunt Breakdown of academic impact, for papers by Thaddeus J. Unger Breakdown of academic impact, for papers by M. Schroeder Breakdown of academic impact, for papers by Nelson B. Freimer Breakdown of academic impact, for papers by Christopher W. Smith Breakdown of academic impact, for papers by John Logothetis Breakdown of academic impact, for papers by Bei Shao Breakdown of academic impact, for papers by Jiayu Fu
Rankless by CCL
2026